Shanghai Aug 27th 2019, Elpiscience Biopharma, Ltd., a clinical stage immuno-oncology company, announces that two key molecules in innate immunity have entered into CMC development stage.
The two therapeutic candidates, anti-CD39 (ES002) and anti-SIRPa (ES004) antibodies, are potentially best-in-class molecules. They harbor the potential to address PD-1/PD-L1 non-responsive tumors by unleashing the power of innate immunity. Scientific data of the two molecules will be presented at the upcoming SITC conference in November 2019, Washington DC.
Elpiscience is a clinical stage biopharmaceutical company focusing on cancer immunotherapy. The company is committed to leading the innovation and development of the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpscience’s first therapeutic product ES101 has entered into clinical trial, and the second innovative product ES102 is IND ready. Elpiscience has a pipeline of more than 10 innovative molecules in discovery, covering a wide range of targets with a particular focus on innate immunity and tumor microenvironment. Elpiscience’s sustainable pipeline forms a strong cornerstone for developing the next generation and more effective immunotherapies. Founded and managed by seasoned executives in the biopharma industry, Elpiscience is backed by top investors such as Lilly Asia Ventures, Hillhouse Capital and CDH Investment.